Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GLUE Stock Forecast 2026-2027
$19.81
Current Price
$1.59B
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GLUE Price Targets
+86.8%
To High Target of $37.00
+51.4%
To Median Target of $30.00
+46.4%
To Low Target of $29.00
GLUE Price Momentum
+13.2%
1 Week Change
+26.7%
1 Month Change
+344.2%
1 Year Change
+26.3%
Year-to-Date Change
-23.1%
From 52W High of $25.77
+464.4%
From 52W Low of $3.51
📊 TOP ANALYST CALLS
Did GLUE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Monte Rosa is one of their latest high-conviction picks.
Latest GLUE Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, GLUE has a bullish consensus with a median price target of $30.00 (ranging from $29.00 to $37.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $19.81, the median forecast implies a 51.4% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Tenthoff at Piper Sandler, projecting a 86.8% upside. Conversely, the most conservative target is provided by Derek Archila at Wells Fargo, suggesting a 46.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GLUE Analyst Ratings
8
Buy
0
Hold
0
Sell
GLUE Price Target Range
Low
$29.00
Average
$30.00
High
$37.00
Current: $19.81
Latest GLUE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GLUE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 18, 2026 | Wells Fargo | Derek Archila | Overweight | Maintains | $29.00 |
| Mar 18, 2026 | Guggenheim | Michael Schmidt | Buy | Maintains | $30.00 |
| Jan 14, 2026 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $37.00 |
| Jan 8, 2026 | Wells Fargo | Derek Archila | Overweight | Maintains | $30.00 |
| Jan 8, 2026 | Guggenheim | Michael Schmidt | Buy | Maintains | $34.00 |
| Dec 16, 2025 | Wells Fargo | Derek Archila | Overweight | Upgrade | $22.00 |
| Nov 7, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $13.00 |
| Mar 21, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $10.00 |
| Mar 21, 2025 | Wedbush | Robert Driscoll | Outperform | Maintains | $17.00 |
| Mar 12, 2025 | LifeSci Capital | Outperform | Initiates | $19.00 | |
| Dec 19, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $11.00 |
| Sep 12, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $11.00 |
| Aug 12, 2024 | Wells Fargo | Derek Archila | Overweight | Maintains | $17.00 |
| Jun 28, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $16.00 |
| May 22, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $11.00 |
| Feb 15, 2024 | Wedbush | Robert Driscoll | Outperform | Initiates | $11.00 |
| Oct 19, 2023 | JP Morgan | Eric Joseph | Overweight | Maintains | $11.00 |
| Aug 11, 2023 | Credit Suisse | Richard Law | Neutral | Reiterates | $11.00 |
| May 12, 2023 | Credit Suisse | Richard Law | Neutral | Reiterates | $11.00 |
| Mar 17, 2023 | Credit Suisse | Richard Law | Neutral | Maintains | $11.00 |
Monte Rosa Therapeutics, Inc. (GLUE) Competitors
The following stocks are similar to Monte Rosa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GLUE
Monte Rosa
mkt cap
1.58B
Monte Rosa Therapeutics, Inc. (GLUE) Financial Data
Monte Rosa Therapeutics, Inc. has a market capitalization of $1.59B with a P/E ratio of 49.2x. The company generates $123.67M in trailing twelve-month revenue with a -31.2% profit margin.
Revenue growth is -95.4% quarter-over-quarter, while maintaining an operating margin of -1,787.7% and return on equity of -16.9%.
Valuation Metrics
Market Cap
$1.59B
Enterprise Value
$1.24B
P/E Ratio
49.2x
PEG Ratio
-0.1x
Price/Sales
12.8x
Growth & Margins
Revenue Growth (YoY)
-95.4%
Gross Margin
N/A
Operating Margin
-1,787.7%
Net Margin
-31.2%
EPS Growth
-95.4%
Financial Health
Cash/Price Ratio
+23.8%
Current Ratio
6.1x
Debt/Equity
16.8x
ROE
-16.9%
ROA
-7.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Monte Rosa Therapeutics, Inc. (GLUE) Business Model
About Monte Rosa Therapeutics, Inc.
What They Do
Develops molecular glue degraders for targeted therapies.
Business Model
The company operates as a clinical-stage biotechnology firm, focusing on the discovery and development of molecular glue degraders (MGDs) that leverage the body's protein degradation systems. It generates revenue primarily through partnerships, grants, and potential future product sales once its therapies gain regulatory approval.
Additional Information
Monte Rosa Therapeutics utilizes its proprietary QuEEN platform, which combines artificial intelligence with experimental techniques to facilitate the design of MGD candidates. The company's pipeline includes promising assets like MRT-2359 for treating various cancers and MRT-6160 and MRT-8102 for addressing oncology and autoimmune conditions, positioning it well within the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
150
CEO
Dr. Markus Warmuth M.D.
Country
United States
IPO Year
2021
Website
www.monterosatx.comMonte Rosa Therapeutics, Inc. (GLUE) Latest News & Analysis
Latest News
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
1 month ago
Quick Summary
Monte Rosa Therapeutics reported positive Phase 1 data for MRT-8102, with further Phase 2 studies planned for CVD-risk and other conditions in 2026-2027. The company secured $345M in financing to support operations.
Why It Matters
Positive clinical data and upcoming trial initiations signal potential market confidence in Monte Rosa Therapeutics' pipeline, which may enhance stock value and attract investment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Monte Rosa Therapeutics (GLUE) reported a quarterly loss of $0.55 per share, missing the Zacks Consensus Estimate of a $0.47 loss and compared to earnings of $0.23 per share last year.
Why It Matters
Monte Rosa's larger-than-expected quarterly loss and decline from last year's earnings signal potential operational challenges, affecting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Monte Rosa Therapeutics has secured a clinical supply agreement to support a Phase 2 trial of MRT-2359 combined with Apalutamide for treatment evaluation.
Why It Matters
The clinical supply agreement signals progress in Monte Rosa's drug development, potentially boosting stock value if Phase 2 trial results are positive, impacting market confidence and future partnerships.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
1 month ago
Quick Summary
Monte Rosa Therapeutics (GLUE) is expected to report earnings that may exceed forecasts, driven by favorable key factors. Investors should be aware of these expectations ahead of the report.
Why It Matters
Monte Rosa Therapeutics (GLUE) may report stronger earnings, indicating potential stock price appreciation and attracting investor interest, affecting overall market sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Monte Rosa Therapeutics reported positive Phase 1/2 results for MRT-2359 with enzalutamide in mCRPC patients, showing 100% PSA response and 67% overall disease control. A Phase 2 study is planned for Q3 2026.
Why It Matters
Positive clinical results for MRT-2359 combined with enzalutamide indicate strong potential for treatment in mCRPC, enhancing Monte Rosa's prospects and possibly driving stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 3:10 p.m., led by CEO Markus Warmuth, M.D.
Why It Matters
Monte Rosa's participation in key investor conferences highlights its commitment to transparency and engagement, potentially boosting investor confidence and interest in its innovative drug development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GLUE Stock
What is Monte Rosa Therapeutics, Inc.'s (GLUE) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Monte Rosa Therapeutics, Inc. (GLUE) has a median price target of $30.00. The highest price target is $37.00 and the lowest is $29.00.
Is GLUE stock a good investment in 2026?
According to current analyst ratings, GLUE has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GLUE stock?
Wall Street analysts predict GLUE stock could reach $30.00 in the next 12 months. This represents a 51.4% increase from the current price of $19.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Monte Rosa Therapeutics, Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, focusing on the discovery and development of molecular glue degraders (MGDs) that leverage the body's protein degradation systems. It generates revenue primarily through partnerships, grants, and potential future product sales once its therapies gain regulatory approval.
What is the highest forecasted price for GLUE Monte Rosa Therapeutics, Inc.?
The highest price target for GLUE is $37.00 from Edward Tenthoff at Piper Sandler, which represents a 86.8% increase from the current price of $19.81.
What is the lowest forecasted price for GLUE Monte Rosa Therapeutics, Inc.?
The lowest price target for GLUE is $29.00 from Derek Archila at Wells Fargo, which represents a 46.4% increase from the current price of $19.81.
What is the overall GLUE consensus from analysts for Monte Rosa Therapeutics, Inc.?
The overall analyst consensus for GLUE is bullish. Out of 9 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are GLUE stock price projections?
Stock price projections, including those for Monte Rosa Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 4:48 AM UTC